12 Health Care Stocks Moving In Wednesday's After-Market Session
Citius Pharmaceuticals Inc CTXR
$0.57
▼ -9.81%
($-0.06)
🗓️ Earnings Next Week
Open
$0.62
Prev Close
$0.63
Day Range
$0.56 – $0.63
52W Range
$0.47 – $2.19
Market Cap
$15.65M
Beta
0.98
EPS (TTM)
$-2.59
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-08-03 |
| Shares Out. | 27,450,000 |
| Website | citiuspharma.com/ ↗ |
| Phone | 19089676677 |
| Employees | 23 |
| Revenue | $1.7M |
| Gross Profit | $1.3M |
| Net Income | -$28.1M |
| Total Assets | $132.5M |
| Total Liabilities | $63.5M |
| Equity | $69.1M |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Citius Pharmaceuticals Inc is a publicly traded company under the ticker symbol CTXR on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)